Pharmaceutics_R&D
3.9K views | +0 today
Follow
Pharmaceutics_R&D
Pharmaceutical companies R&D specifically in neuroscience, CNS disease, pain and electrophysiology
Your new post is loading...
Your new post is loading...
Scooped by Julien Hering, PhD
Scoop.it!

L'irrésistible déclin de l’industrie pharmaceutique en France

L'irrésistible déclin de l’industrie pharmaceutique en France | Pharmaceutics_R&D | Scoop.it

Baisses de prix, impact des génériques : le marché du médicament devrait continuer de décliner cette année en France, selon une étude d’IMS Health. Une embellie serait possible en 2014, en fonction des décisions politiques.


Alors que les plans sociaux se poursuivent dans l’industrie pharmaceutique, les perspectives sur le marché français sont toujours sombres. Après avoir connu la première récession de son histoire en 2012, avec une chute de 2,3% en valeur, le marché des médicaments en ville devrait s’effondrer de 3,4% cette année, selon l’étude présentée ce mardi par le cabinet de conseil pour les acteurs de la santé IMS Health. (...) L'Usine Nouvelle, par Gaëlle Fleitour19 mars 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

» Troubles bipolaires: AstraZeneca lance Bipolife®, un outil inédit pour les malades et leur entourage

» Troubles bipolaires: AstraZeneca lance Bipolife®, un outil inédit pour les malades et leur entourage | Pharmaceutics_R&D | Scoop.it

AstraZeneca a lancé Bipolife® : le premier outil interactif à visée psychoéducative spécifiquement dédié aux troubles bipolaires. Développé en collaboration avec l’entreprise Ubisoft et sous la supervision d’un comité scientifique, Bipolife® a pour objectif d’aider les personnes souffrant de troubles bipolaires à mieux comprendre leur maladie et à identifier les comportements quotidiens qui influent sur son évolution. (...) - MyPharma, 01/04/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Why all pharmaceutical research should be made open access

Why all pharmaceutical research should be made open access | Pharmaceutics_R&D | Scoop.it

The government wants to make all publicly funded research available – but the same must be demanded of pharmas also

I recently had lunch with as staunch an advocate for open access as you'll ever meet (I won't name him, because it would be rude to attribute casual remarks to him without permission). We were talking about plans to mandate free and open publication of publicly funded scientific research. In the USA, there's the Federal Public Research Act, and in the UK, there's the coalition government's announcement that publicly funded research should be made available at no cost, under a Creative Commons licence that permits unlimited copying. (...) by Cory Doctorow, The Guardian, 20 november 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation - GaBI Journal

The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation - GaBI Journal | Pharmaceutics_R&D | Scoop.it

Background: Due to the declining innovativeness of the classic R & D model in the original pharmaceutical industry, the generic pharmaceutical industry is aiming to become an innovation generator itself. 

Results: Those generic pharmaceutical firms that implement new competitive strategies have integrated re-innovation design into their product portfolio to provide more personalized, cost-effective products to meet the healthcare systems’, policymakers’ and patients’ demand for high quality accessible treatments. This re-orientation hopes to better face the changing competition challenges in both mature and developing markets. 
Conclusions: A new approach to innovativeness together with a value proposition strategy aims to deliver high quality products to patients.

(...) - by Barei F. et al., Generics and Biosimilars Initiative Journal (GaBI Journal). 2013;2(1)


more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

4 Key Drug Approvals Expected In The Next 30 Days

4 Key Drug Approvals Expected In The Next 30 Days | Pharmaceutics_R&D | Scoop.it

Biogen Idec's BG-12, United Therapeutics' oral Remodulin, Johnson & Johnson's Invokana and Allergan's Levadex are all nearing their possible launches

Investing in drug stocks isn't quite like investing in other stocks. While drugmakers' shares can move on earnings and buyout news like anyone else's, what really gets investors excited is an FDA decision allowing a new drug on the market. Here are some of the most important drugs awaiting approval in the next month. (...) - by Amy Reeves, Investors.com, 03/15/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Réputation des Big Pharma américaines

Parmi les Big Pharma, Johson&Johson est la seule survivante dans le TOP60 des « most visible companies » établi tous les ans par Harris, avec une excellente 5e place.
Pfizer n’y figure plus depuis 2 ans.
Globalement, l’industrie pharmaceutique a un rating négatif à 40%.
à noter que Facebook n’occupe qu’une modeste 42e place, loin derrière Amazon (1er), Apple (2e) et Google (4e) (...) - Blog "Intelligene scientifique & veille", 14/02/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Legendary Drug Industry Executives Warn U.S. Science Cuts Endanger The Future - Forbes

Legendary Drug Industry Executives Warn U.S. Science Cuts Endanger The Future - Forbes | Pharmaceutics_R&D | Scoop.it

Biomedical research and innovation are crucial to improving America’s health, global competitiveness, and economic growth, as both President Obama and House Majority Leader Cantor have stressed in recent weeks. In the wake of the sequester, and as the President and Congress move ahead with budget negotiations, now is the time for both parties to translate into action their bipartisan commitment to our nation’s science investment by restoring the budgets of the National Institutes of Health (NIH) and other science agencies that support basic biomedical research in universities and medical schools in all 50 states – an area of federal spending that is highly productive and a critical investment. (...) - by Marc Tessier-Lavigne, President, The Rockefeller University and former Chief Scientific Officer, Genentech Inc. (left); P. Roy Vagelos, Chairman, Regeneron Pharmaceuticals, and Retired Chairman and CEO, Merck & Co., Inc. (center); and Elias ZerhouniPresident R&D Sanofi and former Director of the National Institutes of Health., Forbes, 03/06/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Grünenthal et Ethypharm concluent un accord de licence dans le traitement de la douleur

Grünenthal et Ethypharm concluent un accord de licence dans le traitement de la douleur | Pharmaceutics_R&D | Scoop.it

Le groupe pharmaceutique allemand Grünenthal et Ethypharm, société française spécialisée dans les technologies de formulation innovantes, ont conclut un accord de licence, de distribution et d’approvisionnement exclusif. Cet accord permet à la société de commercialiser les comprimés sublinguaux à base de fentanyl d’Ethypharm pour le traitement des accès de douleur dus au cancer sur des marchés européens sélectionnés. (...) MyPharma Editions, 06/03/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Alltrials contd. - UCB warns of data ‘voyeurism’

Alltrials contd. - UCB warns of data ‘voyeurism’ | Pharmaceutics_R&D | Scoop.it
UCB chief executive Roch Doliveux has attacked the idea of making all clinical trial data publicly available, saying it could be ‘dangerous and misleading’. (...) - by Adam Hill, Pharmafile via PharmaGossip, 27/02/2013
more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Europe bets on drug discovery

Europe bets on drug discovery | Pharmaceutics_R&D | Scoop.it

Proponents hope consortium will revive flagging industry.


Two sites shuttered by the pharmaceutical giant Merck, one in Scotland and one in the Netherlands, will soon be humming again with the work of drug discovery. But the hum will not be business as usual. It will be the sound of a public–private consortium placing a high-stakes wager: a nearly €200-million (US$271-million) bet that it can boost a languishing pharmaceutical sector by fusing academic innovation with industrial-scale screening, using robots to test chemicals for biological activity. (...) - by Monya Baker, Nature07 February 2013

more...
James A Smith MCIM's curator insight, February 25, 2013 7:17 AM

Some big money investment here and interesting to see from a business model perspective

Scooped by Julien Hering, PhD
Scoop.it!

The 25 most influential people in biopharma today - 2013

The 25 most influential people in biopharma today - 2013 | Pharmaceutics_R&D | Scoop.it
Who in this business hasn't seen billions incinerated in pursuit of sheer folly?


Influence is a fungible asset.

A lot of cash on hand can help tremendously, of course. But at this stage, who in this business hasn't seen billions incinerated in pursuit of sheer folly? Far more influential is the savvy executive who can marshal experts as well as financial resources in pursuit of a smarter, better, faster way to develop and market important new drugs. (...) - by John CarrollFierceBiotech

more...
No comment yet.
Rescooped by Julien Hering, PhD from Pharma_News
Scoop.it!

Will "Robust Pipeline" Yield More New Drugs?

Will "Robust Pipeline" Yield More New Drugs? | Pharmaceutics_R&D | Scoop.it

Biopharmaceutical companies are touting their huge investment in R&D, which has filled the drug pipeline with more potential first-in-class medicines, including orphan drugs, personalized medicines and new therapies based on novel scientific strategies. A report by the Analysis Group for the Pharmaceutical Research and Manufacturers of America (PhRMA) documents more than 5,000 new medicines in the pipeline globally, many for untreated diseases and life-threatening conditions. The promise is that this more robust pipeline will lead to more new critical therapies for patients.

Yet, the data also reveals that most of these therapies are in early stages of development:  less than 1000 of the 5400 products in clinical development have reached stage III, and only 82 are headed for market following approval by the Food and Drug Administration. The attrition from phase II to phase III remains very high despite a range of scientific advances and regulatory improvements. Of nearly 3000 new molecular entities (NMEs) to treat cancer, only 288 have reached stage III clinical trials, and only  a handful make it to market. Therapies for infectious diseases seem to have a higher success rate, with about 700 investigational projects yielding 22 recent approvals. Certainly a higher “early kill” rate may be a sign of progress in the  risky world of pharma R&D, where a key goal is to avoid costly phase III studies that won’t pass muster with FDA. The current study doesn’t provide the historical data that could tell more about whether pharma R&D is becoming more productive, but there doesn’t seem to much evidence of progress.

A more telling sign is the recent rise in FDA’s approval numbers for NMEs, reaching almost 40 in 2012 and still providing steady good news for sponsors. The promise is that more INDs eventually will yield more new approved medicines. “There are no guarantees” from a stronger and more diverse pipeline, but the study reveals the “depth of possibilities,” observed Genia  Long of the Analysis Group in a PhRMA webinar. However, it also is important for pharma to reduce the overall cost of developing new drugs, and that will require more informative early stage research strategies that efficiently separate potential winners from likely losers. Researchers are making progress in developing treatments for Alzheimer’s disease, pointed out Eli Lilly CEO John Lechleiter, acknowledging that success “will require longer, more expensive studies to show benefit for patients.”

The PhRMA report aims to demonstrate to the public and policymakers the high value of biopharmaceutical R&D and the importance of continuing government support for FDA programs and research funded by the National Institutes of Health. It also highlights the value – and the need to pay for – new therapies to treat rare diseases and conditions that currently lack effective treatment. Ultimately, these new, costly research endeavors could lead to cures and preventives for cancer, Alzheimer’s and other devastating illnesses that affect millions. But the costs for individual patients may be enormous, and it remains to be seen if public and private health programs will pay for them.

 


Via Lionel Reichardt / le Pharmageek, Chatu Jayadewa
more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Crowdfunding Is Coming to Biotech, so Get Ready for a Wild Ride | Xconomy

Crowdfunding Is Coming to Biotech, so Get Ready for a Wild Ride | Xconomy | Pharmaceutics_R&D | Scoop.it

Most biotech pros will shrug, or chuckle, if you ask whether crowdfunding will transform life sciences financing in the U.S.


This, after all, is an industry where you often need to raise at least $50 million or $100 million to even have a chance at developing a new drug or medical device. Scraping together a few thousand bucks from individuals on the Internet isn’t going to go very far. One venture capitalist recently told me, “there are a lot of things I worry about, but crowdfunding isn’t one of them.” (...) - By Luke Timmerman, Xconomy, 1/28/2013

more...
No comment yet.
Rescooped by Julien Hering, PhD from All about Pharma by Pharmacomptoir
Scoop.it!

Pharma Business

Pharma Business | Pharmaceutics_R&D | Scoop.it

A la recherche du ePatient. (RT @laumacom: A la recherche du ePatient. http://t.co/Nv8KD0FUnr (via @pharmacomptoir) #ePatient #esante)


Via Pharmacomptoir / Corinne Thuderoz
more...
No comment yet.
Rescooped by Julien Hering, PhD from eLearning - entre pedagogies et technologies - between pedagogy et technology
Scoop.it!

Flipped Classrooms: Improved Test Scores and Teacher Satisfaction

Flipped Classrooms: Improved Test Scores and Teacher Satisfaction | Pharmaceutics_R&D | Scoop.it
ClassroomWindow™: Providing an unprecedented view into what works - and for which kids - in U.S. classrooms.
Via Marcel Lebrun
more...
vgpascal's curator insight, April 14, 2013 1:55 AM

Les effets des classés inversées sur l'apprentissage et sur la satisfaction de "donner des occasions d'apprendre" ;-)

Matthieu CLEMENT's comment, April 17, 2013 12:58 AM
Cette méthode marche très bien dans le cadre de l'université. Pour l'avoir testé en classe de seconde en France, c'est beaucoup plus difficile dans le secondaire. http://aggiornamento.hypotheses.org/1238
Bernard Buchel's curator insight, April 21, 2013 7:58 AM

Marcel Lebrun souligne : "De meilleures attitudes des étudiants, des enseignants davantage satisfaits, de meilleurs scores (standardisés) aussi aux évaluations. Pour ce dernier point, tout dépend de ce que l'on "mesure" mais en tout cas, pas de perte dans les connaissances ( les savoirs) contrairement à ce que pourraient penser les grognons. Il faudrait faire de cette méthode une priorité institutionnelle !"

Bref il n'y a pas que les techniques numériques pour renouveler la pédagogie.

Scooped by Julien Hering, PhD
Scoop.it!

Drug-company data vaults to be opened

Drug-company data vaults to be opened | Pharmaceutics_R&D | Scoop.it

European agency will publish firms’ clinical-trial results.


International calls for the pharmaceutical industry to share the results of clinical trials have grown ever more intense amid revelations that high-profile companies have hidden crucial data on safety and efficacy. Now Europe is moving towards measures that would significantly increase disclosure of such data. (...) - by Daniel Cressey, Nature, 27 March 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

US pharma: 465 drugs in R&D for chronic diseases affecting over-65s

US pharma: 465 drugs in R&D for chronic diseases affecting over-65s | Pharmaceutics_R&D | Scoop.it

US biopharmaceutical companies are currently developing 465 new medicines that target the 10 leading chronic conditions affecting people aged 65 and over, according to new industry data.

The medicines, which are all now in clinical trials or under review by the Food and Drug Administration (FDA), are diverse in scope, notes the Pharmaceutical Research and Manufacturers of America (PhRMA), which has published the data. (...) - by Lynne Taylor, PharmaTimes, March 22, 2013

more...
NCTC's curator insight, March 29, 2013 4:19 AM

Interesting, also in light of the Dutch IEMO project which aims at including seniors in clinical trials to measure the effect durgs have have on them.

Scooped by Julien Hering, PhD
Scoop.it!

AstraZeneca losing 1,600 jobs, with 650 positions cut at U.S. sites

AstraZeneca losing 1,600 jobs, with 650 positions cut at U.S. sites | Pharmaceutics_R&D | Scoop.it

A major reorganization of its research operations will result in 1,600 jobs being cut by AstraZeneca, with roughly 650 positions slashed in the U.S. (...) - By Russ Britt, MarketWatch blog "Health Exchange", March 18, 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Biomedical hiring : Naturejobs

Many drug-makers hope to recruit in next few years.


Many biopharmaceutical companies plan to hire scientists in the next three years, according to a report published on 4 February by the PwC Health Research Institute in Washington DC, part of London-based professional-services firm PwC. New Chemistry: Getting the Biopharmaceutical Talent Formula Right, which is based on surveys of company executives and recruiters, finds that 72% of drug-makers plan to boost their research capacity in the next 12 months by hiring scientists, creating partnerships or improving infrastructure. The results of the survey suggest that jobs will grow by about 30% among US medical scientists, biochemists and biophysicists by 2020. Responding companies want recruits who can develop and manage external partnerships, and who know about regulatory science, bioinformatics and outcomes research. Early-career scientists looking for opportunities need to “think about the entire value chain that leads to the development of a drug or medical device”, says Christopher Khoury, a senior manager at the Health Research Institute and lead author of the report. - Nature 494, 509 (2013), Published online 27 February 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Novartis CEO: The Age Of Massive Blockbuster Drugs Is Over

Novartis CEO: The Age Of Massive Blockbuster Drugs Is Over | Pharmaceutics_R&D | Scoop.it

Big pharma needs to change its whole business model.


The business model for large pharmaceutical companies hasn't changed for decades.


You target a huge population, like people with heart disease, find and patent a drug that's at least marginally better than current treatments, and make billions. It's worked pretty well for a long time. (..) - by Max Nisen, Business Insider, Mar. 4, 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

LEO Pharma and 4SC Discovery Form Pact for Up to

BALLERUP, Denmark and PLANEGG-MARTINSRIED, Germany , Feb. 26, 2013 /CNW/ - LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis. (...) - biospace.com, 02/26/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Qui veut sauver les emplois de la pharma ?

Qui veut sauver les emplois de la pharma ? | Pharmaceutics_R&D | Scoop.it

La chute de l’emploi dans le secteur pharmaceutique n’est pas inexorable, estiment les industriels. Chiffres à l’appui, ils ont dégagé les leviers à actionner pour limiter la casse sociale. (...) - Par Gaëlle Fleitour, L'Usine Nouvelle23 janvier 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

How is European pharma responding to stricter transparency laws?

How is European pharma responding to stricter transparency laws? | Pharmaceutics_R&D | Scoop.it
This article is about promotional compliance trends in Europe following the lead of anti-bribery and anti-corruption laws set in the United States.



In this article, we look at European pharma promotional compliance trends as reported in Cegedim Relationship Management’s third annual survey: ‘2012 European Trends in Aggregate Spend, Transparency, and Disclosure’.

The pharmaceutical, medical device and biotech industries are currently witnessing the rise of tighter promotional transparency regulations. As many expected, the stringency of anti-corruption and anti-bribery laws already in place in the United States are beginning to make their way over to Europe, with some countries in Europe already surpassing the enforcement levels set by the US. (...) - by Hannah Blake, pharmaphorum5th February 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Where, Oh Where, Has All The Pharma Talent Gone? // Pharmalot

Where, Oh Where, Has All The Pharma Talent Gone? // Pharmalot | Pharmaceutics_R&D | Scoop.it

File this under ‘sad irony.’ Now that the pharmaceutical industry has tossed thousands of people overboard during the last decade – an estimated 150,000 or so just since 2009 – a slight majority of drugmakers complain that it has become increasingly difficult to find the right talent and most worry they will not have access to the people they need to hire, according to a report from PricewaterhouseCoopers. (...) - By Ed Silverman, PharmalotFebruary 5th, 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Rhenovia invente le patch anti-Alzheimer

Rhenovia invente le patch anti-Alzheimer | Pharmaceutics_R&D | Scoop.it

Spécialiste de la biosimulation pour la recherche pharmaceutique, Rhenovia Pharma, basé à Mulhouse et implanté aux Etats-Unis depuis un an, vient de breveter un patch électronique pour l'administration contrôlée de médicaments. (...) - Les Echos, par CHRISTIAN LIENHARDT | 23/01/2013

more...
No comment yet.